Alirocumab
- Generic Name
- Alirocumab
- Brand Names
- Praluent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1245916-14-6
- Unique Ingredient Identifier
- PP0SHH6V16
- Background
Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutic...
- Indication
Alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor activity that is indicated for:
(i) use in reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease , and/or
...
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolaemia (HoFH), Myocardial Infarction, Stroke, Unstable Angina Pectoris, Primary Hyperlipidemia
- Associated Therapies
- -
TOP 2301: Neoadjuvant Chemo for NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 126
- Registration Number
- NCT06385262
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Sun U. Kwon
- Target Recruit Count
- 200
- Registration Number
- NCT06083961
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-12-21
- Target Recruit Count
- 80
- Registration Number
- NCT06080256
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 50
- Registration Number
- NCT06052020
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Alirocumab in Patients With Sepsis
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Jonathan Sevransky
- Target Recruit Count
- 50
- Registration Number
- NCT05469347
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Alirocumab and Plaque Burden In Familial Hypercholesterolaemia
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Fundación Hipercolesterolemia Familiar
- Target Recruit Count
- 104
- Registration Number
- NCT05465278
- Locations
- 🇪🇸
Fundacion Hipercolesterolemia Familiar, Madrid, Spain
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT05292404
- Locations
- 🇨🇳
nineth people's hospital, School of Medicine, shanghai jiaotong university, Shanghai, Shanghai, China
🇨🇳Shanghai chest hospital, Shanghai, Shanghai, China
🇨🇳Shanghai tongren hospital, Shanghai, Shanghai, China
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05001984
- Locations
- 🇨🇳
Yenchu Huang, Chiayi City, Taiwan
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-11-07
- Target Recruit Count
- 100
- Registration Number
- NCT04781322
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 70
- Registration Number
- NCT04613167
- Locations
- 🇸🇮
University Medical Centre Ljubljana-Department of Vascular diseases and dept. of Cardiology, Ljubljana, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.